Clinical Trial Update: Risk-adapted Therapeutic Strategy in +1q NDMM

View source ↗

Summary

Clinical trial update announcing a risk-adapted therapeutic strategy for newly diagnosed multiple myeloma with +1q abnormalities. The study is not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: FengYan Jin | Conditions: Multiple Myeloma | Status: NOT_YET_RECRUITING